CYTH — Cyclo Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $18.56m
- $20.15m
- $1.08m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.01 | 0.903 | 1.59 | 1.38 | 1.08 |
Cost of Revenue | |||||
Gross Profit | 0.923 | 0.83 | 1.42 | 1.23 | 0.978 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 8.55 | 9.86 | 15.9 | 16.8 | 21.1 |
Operating Profit | -7.54 | -8.96 | -14.3 | -15.5 | -20.1 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -7.53 | -8.94 | -14.3 | -15.5 | -20.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.53 | -8.94 | -14.3 | -15.5 | -20.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.53 | -8.94 | -14.3 | -15.5 | -20.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.53 | -8.94 | -14.3 | -15.5 | -20.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -6.82 | -5.59 | -2.24 | -1.85 | -1.23 |